External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>InnoCare recorded total revenue of RMB188mn in 2Q23, including RMB169mn sales from orelabrutinib (+12% QoQ, +52% YoY).</li><li>In 1H23, the sales of orelabrutinib totalled RMB321mn, +48% YoY, accounting for 33% of our previous full-year estimate.</li><li>In comparison, BGNE’s zanubrutinib achieved US$97mn revenue in China in 1H23, +38% YoY.</li><li>InnoCare’s GP margin (vs total revenue) improved significantly from 77% in 1Q23 to 82% in 2Q23. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare recorded total revenue of RMB188mn in 2Q23, including RMB169mn sales from orelabrutinib (+12% QoQ, +52% YoY).In 1H23, the sales of orelabrutinib totalled RMB321mn, +48% YoY, accounting for 33% of our previous full-year estimate.In comparison, BGNE’s zanubrutinib achieved US$97mn revenue in China in 1H23, +38% YoY.InnoCare’s GP margin (vs total revenue) improved significantly from 77% in 1Q23 to 82% in 2Q23. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare Pharma (9969 HK) – Consistent Results of Orelabrutinib for MS

<ul><li>InnoCare recorded total revenue of RMB189mn in 1Q23, including RMB151mn sales from orelabrutinib (-9% QoQ, +44% YoY).</li><li>The QoQ decrease in sales of orelabrutinib was mainly due to the COVID-19 outbreak and Chinese New Year break in 1Q.</li><li>InnoCare continued to improve its cost efficiency in 1Q23. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare recorded total revenue of RMB189mn in 1Q23, including RMB151mn sales from orelabrutinib (-9% QoQ, +44% YoY).The QoQ decrease in sales of orelabrutinib was mainly due to the COVID-19 outbreak and Chinese New Year break in 1Q.InnoCare continued to improve its cost efficiency in 1Q23. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare Pharma (9969 HK) – Eyes on Next Steps of Orelabrutinib for MS

<ul><li>InnoCare recorded total revenue of RMB625mn in FY22, including RMB566mn sales from orelabrutinib (+164% YoY vs RMB215mn in FY21).</li><li>Sales of orelabrutinib in 4Q22 was RMB166mn, slightly lower compared to RMB183mn in 3Q22 mainly due to COVID-19 interruptions.</li><li>The strong sales growth of orelabrutinib in FY22 was mainly driven by the increasing market penetration of the drug after NRDL inclusion effective since Jan 2022.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare recorded total revenue of RMB625mn in FY22, including RMB566mn sales from orelabrutinib (+164% YoY vs RMB215mn in FY21).Sales of orelabrutinib in 4Q22 was RMB166mn, slightly lower compared to RMB183mn in 3Q22 mainly due to COVID-19 interruptions.The strong sales growth of orelabrutinib in FY22 was mainly driven by the increasing market penetration of the drug after NRDL inclusion effective since Jan 2022.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare Pharma (9969 HK) – Positive PoC data of orelabrutinib for MS

<ul><li>Biogen terminated partnership with InnoCare. On 15 Feb, Biogen terminated the collaboration with InnoCare on orelabrutinib for the treatment of multiple sclerosis (MS) and other autoimmune diseases.</li><li>The two parties started the collaboration in Jul 2021, and since then, InnoCare has received US$125mn upfront payment, and was eligible to receive up to US$812.5mn milestone payment and future sales royalties according to the original agreement.</li><li>However, due to the current termination, future payment will not happen, while InnoCare doesn’t need to return the upfront payment. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biogen terminated partnership with InnoCare. On 15 Feb, Biogen terminated the collaboration with InnoCare on orelabrutinib for the treatment of multiple sclerosis (MS) and other autoimmune diseases.The two parties started the collaboration in Jul 2021, and since then, InnoCare has received US$125mn upfront payment, and was eligible to receive up to US$812.5mn milestone payment and future sales royalties according to the original agreement.However, due to the current termination, future payment will not happen, while InnoCare doesn’t need to return the upfront payment. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare Pharma (9969 HK) – Breakup with Biogen on Orelabrutinib

<ul><li>InnoCare recorded total revenue of RMB196mn in 3Q22, including RMB183mn sales from orelabrutinib (+64% QoQ, +147 YoY).</li><li>Sales of orelabrutinib during 9M22 reached RMB400mn, representing +129% YoY growth.</li><li>The strong sales growth was mainly driven by the increasing market penetration after NRDL inclusion effective since Jan 2022. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare recorded total revenue of RMB196mn in 3Q22, including RMB183mn sales from orelabrutinib (+64% QoQ, +147 YoY).Sales of orelabrutinib during 9M22 reached RMB400mn, representing +129% YoY growth.The strong sales growth was mainly driven by the increasing market penetration after NRDL inclusion effective since Jan 2022. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

InnoCare Pharma (9969 HK) – Strong sales of orelabrutinib in 3Q22

China

InnoCare Pharma Limited researches, develops, manufactures, and distributes pharmaceuticals. The Company produces antibiotic drugs, respiratory drugs, cardiovascular drugs, vitamin tablets, health care drugs, and other related products. InnoCare Pharma markets its products throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

InnoCare Pharma Ltd (9969 HK)

InnoCare Pharma (9969 HK) – Consistent Results of Orelabrutinib for MS

n 1H23, the sales of orelabrutinib totalled RMB321mn, +48% YoY, accounting for 33% of our previous full-year estimate. In comparison, BGNE’s...

CMB International

InnoCare Pharma (9969 HK) – Eyes on Next Steps of Orelabrutinib for MS

The QoQ decrease in sales of orelabrutinib was mainly due to the COVID-19 outbreak and Chinese New Year break in 1Q. InnoCare continued to improve...

CMB International

InnoCare Pharma (9969 HK) – Positive PoC data of orelabrutinib for MS

InnoCare recorded total revenue of RMB625mn in FY22, including RMB566mn sales from orelabrutinib (+164% YoY vs RMB215mn in FY21).

CMB International

InnoCare Pharma (9969 HK) – Breakup with Biogen on Orelabrutinib

On 15 Feb, Biogen terminated the collaboration with InnoCare on orelabrutinib for the treatment of multiple sclerosis (MS) and other autoimmune...

CMB International

InnoCare Pharma (9969 HK) – Strong sales of orelabrutinib in 3Q22

InnoCare recorded total revenue of RMB196mn in 3Q22, including RMB183mn sales from orelabrutinib (+64% QoQ, +147 YoY). Sales of orelabrutinib...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)